Novel strategy using live non-pathogenic Leishmania expressing selected parasite antigens as a candidate vaccine for leishmaniasis
2011

New Vaccine Strategy for Leishmaniasis Using Non-Pathogenic Parasites

Sample size: 20 publication Evidence: moderate

Author Information

Author(s): Sima Rafati, Amir Mizbani, Tahere Taheri, Farnaz Zahedifard, Yasaman Taslimi, Barbara Papadopoulou

Primary Institution: Pasteur Institute of Iran

Hypothesis

Can non-pathogenic Leishmania expressing selected antigens serve as an effective vaccine for leishmaniasis?

Conclusion

The study found that a recombinant non-pathogenic Leishmania vaccine elicited strong protective immunity in mice against leishmaniasis.

Supporting Evidence

  • Previous studies have shown that L. tarentolae can be used as a live vaccine against L. donovani.
  • Immunization with recombinant L. tarentolae A2 led to a significant decrease in parasite burdens in the liver and spleen of mice.
  • Protection was associated with a Th1 cell-mediated immune response.

Takeaway

Scientists are trying to use a harmless type of parasite to help protect against a disease caused by other harmful parasites.

Methodology

The study involved immunizing BALB/c mice with recombinant L. tarentolae expressing the A2 protein and assessing immune responses and parasite burdens.

Participant Demographics

BALB/c mice were used in the study.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication